Literature DB >> 28898389

Racial Differences in the Association Between Apolipoprotein E Risk Alleles and Overall and Total Cardiovascular Mortality Over 18 Years.

Kumar B Rajan1, Lisa L Barnes2,3, Robert S Wilson2,3, Elizabeth A McAninch4, Jennifer Weuve5, Dominique Sighoko6, Denis A Evans1.   

Abstract

OBJECTIVES: To examine the difference in the association between apolipoprotein (APO)E allele and overall and cardiovascular mortality between African Americans (AAs) and European Americans (EAs).
DESIGN: Longitudinal, cohort study of 18 years.
SETTING: Biracial urban US population sample. PARTICIPANTS: 4,917, 68% AA and 32% EA. MEASUREMENTS: APOE genotype and mortality based on National Death Index.
RESULTS: A higher proportion of AAs than of EAs had an APOE ε2 allele (ε2ε2/ε2ε3/ε2ε4; 22% vs 13%) and an APOE ε4 allele (ε3ε4/ε4ε4; 33% vs 24%). After adjusting for known risk factors, the risk of mortality was 19% less with the APOE ε2 allele (hazard ratio (HR) = 0.81, 95% confidence interval (CI) = 0.76-0.87), and the risk of cardiovascular mortality was 35% less (HR = 0.65, 95% CI = 0.58-0.76) than with the ε3ε3 allele. The risk of mortality was 10% greater with the APOE ε4 allele (HR = 1.10, 95% CI = 1.04-1.16), and the risk of cardiovascular mortality was 20% greater (HR = 1.20, 95% CI = 1.07-1.29) than with the ε3ε3 allele. No difference in the association between APOE allele and mortality was observed between AAs and EAs.
CONCLUSION: The APOE ε4 allele increased the risk of overall and cardiovascular mortality, whereas the APOE ε2 allele decreased the risk of overall and cardiovascular mortality. There was no racial difference in the association between these alleles and mortality.
© 2017, Copyright the Authors Journal compilation © 2017, The American Geriatrics Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28898389      PMCID: PMC6201232          DOI: 10.1111/jgs.15059

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  32 in total

1.  Mortality differences by APOE genotype estimated from demographic synthesis.

Authors:  Douglas C Ewbank
Journal:  Genet Epidemiol       Date:  2002-02       Impact factor: 2.135

2.  Cognitive activity and incident AD in a population-based sample of older persons.

Authors:  R S Wilson; D A Bennett; J L Bienias; N T Aggarwal; C F Mendes De Leon; M C Morris; J A Schneider; D A Evans
Journal:  Neurology       Date:  2002-12-24       Impact factor: 9.910

3.  Apolipoprotein E genotyping by one-stage PCR.

Authors:  P R Wenham; W H Price; G Blandell
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

4.  Effects of the APOE ε2 allele on mortality and cognitive function in the oldest old.

Authors:  Rune Lindahl-Jacobsen; Qihua Tan; Jonas Mengel-From; Kaare Christensen; Almut Nebel; Lene Christiansen
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-10-09       Impact factor: 6.053

5.  Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia.

Authors:  Kumar B Rajan; Robert S Wilson; Jennifer Weuve; Lisa L Barnes; Denis A Evans
Journal:  Neurology       Date:  2015-06-24       Impact factor: 9.910

6.  Protective effect of apoE epsilon 2 in Alzheimer's disease.

Authors:  R Benjamin; A Leake; F K McArthur; P G Ince; J M Candy; J A Edwardson; C M Morris; E Bjertness
Journal:  Lancet       Date:  1994-08-13       Impact factor: 79.321

7.  Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status.

Authors:  Denis A Evans; David A Bennett; Robert S Wilson; Julia L Bienias; Martha Clare Morris; Paul A Scherr; Liesi E Hebert; Neelum Aggarwal; Laurel A Beckett; Rajiv Joglekar; Elizabeth Berry-Kravis; Julie Schneider
Journal:  Arch Neurol       Date:  2003-02

8.  Birth cohort differences in the prevalence of longevity-associated variants in APOE and FOXO3A in Danish long-lived individuals.

Authors:  Marianne Nygaard; Rune Lindahl-Jacobsen; Mette Soerensen; Jonas Mengel-From; Karen Andersen-Ranberg; Bernard Jeune; James W Vaupel; Qihua Tan; Lene Christiansen; Kaare Christensen
Journal:  Exp Gerontol       Date:  2014-05-05       Impact factor: 4.032

9.  Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease.

Authors:  M Albert; L A Smith; P A Scherr; J O Taylor; D A Evans; H H Funkenstein
Journal:  Int J Neurosci       Date:  1991-04       Impact factor: 2.292

10.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

View more
  18 in total

1.  Reserve and Alzheimer's disease genetic risk: Effects on hospitalization and mortality.

Authors:  Teresa Jenica Filshtein; Willa D Brenowitz; Elizabeth Rose Mayeda; Timothy J Hohman; Stefan Walter; Rich N Jones; Fanny M Elahi; M Maria Glymour
Journal:  Alzheimers Dement       Date:  2019-07       Impact factor: 21.566

2.  Race, APOEɛ4, and Long-Term Cognitive Trajectories in a Biracial Population Sample.

Authors:  Kumar B Rajan; Elizabeth A McAninch; Robert S Wilson; Jennifer Weuve; Lisa L Barnes; Denis A Evans
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

3.  Apolipoprotein E Genotypes, Age, Race, and Cognitive Decline in a Population Sample.

Authors:  Kumar B Rajan; Lisa L Barnes; Robert S Wilson; Jennifer Weuve; Elizabeth A McAninch; Denis A Evans
Journal:  J Am Geriatr Soc       Date:  2018-12-24       Impact factor: 5.562

4.  Data-Driven vs Consensus Diagnosis of MCI: Enhanced Sensitivity for Detection of Clinical, Biomarker, and Neuropathologic Outcomes.

Authors:  Emily C Edmonds; Denis S Smirnov; Kelsey R Thomas; Lisa V Graves; Katherine J Bangen; Lisa Delano-Wood; Douglas R Galasko; David P Salmon; Mark W Bondi
Journal:  Neurology       Date:  2021-08-10       Impact factor: 11.800

5.  Longitudinal Analysis of the Retina and Choroid in Cognitively Normal Individuals at Higher Genetic Risk of Alzheimer Disease.

Authors:  Justin P Ma; Cason B Robbins; Jia Min Lee; Srinath Soundararajan; Sandra S Stinnett; Rupesh Agrawal; Brenda L Plassman; Eleonora M Lad; Heather Whitson; Dilraj S Grewal; Sharon Fekrat
Journal:  Ophthalmol Retina       Date:  2022-03-11

6.  New approaches to genetic predisposition for hemorrhagic stroke in sickle cell disease.

Authors:  Robert J Adams; Rufus O Akinyemi; Mayowa O Owolabi; Dan L Lackland; Bruce Ovbiagele
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-05-27       Impact factor: 3.738

7.  Impact of the Apolipoprotein E ε4 Allele on the Relationship Between Healthy Lifestyle and Cognitive Decline: A Population-Based Study.

Authors:  Klodian Dhana; Neelum T Aggarwal; Kumar B Rajan; Lisa L Barnes; Denis A Evans; Martha C Morris
Journal:  Am J Epidemiol       Date:  2021-07-01       Impact factor: 4.897

8.  Using lipid profiling to better characterize metabolic differences in apolipoprotein E (APOE) genotype among community-dwelling older Black men.

Authors:  Megan M Marron; Steven C Moore; Stacy G Wendell; Robert M Boudreau; Iva Miljkovic; Akira Sekikawa; Anne B Newman
Journal:  Geroscience       Date:  2021-05-15       Impact factor: 7.581

9.  Brain health correlates of mobility-related confidence.

Authors:  C Elizabeth Shaaban; Erica Fan; Brooke N Klatt; Ann D Cohen; Beth E Snitz; Zheming Yu; Brian J Lopresti; Victor L Villemagne; William E Klunk; Howard J Aizenstein; Andrea L Rosso
Journal:  Exp Gerontol       Date:  2022-03-24       Impact factor: 4.253

10.  Genetic risk, adherence to a healthy lifestyle, and cognitive decline in African Americans and European Americans.

Authors:  Klodian Dhana; Lisa L Barnes; Xiaoran Liu; Puja Agarwal; Pankaja Desai; Kristin R Krueger; Thomas M Holland; Shannon Halloway; Neelum T Aggarwal; Denis A Evans; Kumar B Rajan
Journal:  Alzheimers Dement       Date:  2021-07-26       Impact factor: 16.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.